Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
Complete Title: A MULTICENTER, OPEN-LABEL PHASE 1 STUDY
OF U3-1402 IN SUBJECTS WITH METASTATIC OR
UNRESECTABLE EGFR-MUTANT NON-SMALL
CELL LUNG CANCER
Trial Phase: I
Investigator: Christina Baik
This study has two parts: dose escalation and dose expansion. The primary objectives are: •For Dose Escalation, to assess the safety and tolerability of U3-1402 in the study population and to determine the recommended dose for expansion of U3-1402 in the study population •For Dose Expansion, to investigate the antitumor activity of U3-1402 The number of treatment cycles is not fixed in this study. Participants will continue study treatment (for approximately 36 months) until they decide not to (withdraw consent), their disease gets worse [progressive disease (PD)], or side effects become unacceptable (unacceptable toxicity) or other stopping reasons have been met.
Keywords:
- Lung Carcinoma, Non-Small-Cell (NSCLC)
- Carcinoma, Bronchogenic
- Neoplasms, Bronchial
- Neoplasms, Thoracic
- Respiratory Tract Diseases
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I
Christina Baik
RG1003503
NCT03260491
A MULTICENTER, OPEN-LABEL PHASE 1 STUDY
OF U3-1402 IN SUBJECTS WITH METASTATIC OR
UNRESECTABLE EGFR-MUTANT NON-SMALL
CELL LUNG CANCER
Lung Carcinoma, Non-Small-Cell (NSCLC)
Carcinoma, Bronchogenic
Neoplasms, Bronchial
Neoplasms, Thoracic
Respiratory Tract Diseases